Android Apple

Amgen's stock slides 7.8% premarket after weight-loss drug data lags analyst expectations

By MarketWatch   |   3 weeks ago
Amgen's stock slides 7.8% premarket after weight-loss drug data lags analyst expectations

Amgen Inc.'s stock fell 7.8% after announcing results of MariTide weight-loss treatment trial showing up to 20% average weight loss at 52 weeks, slightly below analyst expectations. The treatment offers monthly dosing and promising cardiometabolic improvements.

Read More

Did you find this insightful?

close

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.